Skip to Content

Vertex Pharmaceuticals Inc VRTX Stock Quote

| Rating as of


Last close prices updated as of Jan 27, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 321.45
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Large Growth
  • Day Range 319.58  –  323.67
  • Year Range 225.28  –  324.75
  • Market Cap 82.5135 Bil
  • Volume / Avg 1.3 Mil /  1.4 Mil
  • Price / Sales 9.54
  • Price / Book 6.33
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis VRTX

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Vertex's Narrow Moat Based on Strong Intangible Assets; Positive Outlook for the Firm

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

Vertex Pharmaceuticals, which was once known for discovering Incivek, a blockbuster hepatitis C drug is now overshadowed by a robust cystic fibrosis franchise. Vertex's approved cystic fibrosis drugs are Kalydeco, Orkambi, Symdeko, and Trikafta, which will make Vertex eligible to treat about 90% of the CF population, assuming international and pediatric approvals. We expect Vertex to maintain its dominant position in CF, given the strong efficacy of its therapies, lengthy patents, and lack of competition, while developing pipeline candidates in other rare indications to spur growth.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics VRTX

Company Profile VRTX

Business Description

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

50 Northern Avenue
Boston, MA, 02210
Industry Biotechnology
Employees 3,900

Related Articles VRTX

FAQs for Vertex Pharmaceuticals Inc Stock

No. VRTX does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

VRTX’s market cap is 82.51 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

VRTX’s stock style is Large Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

VRTX’s price/sales is 9.54.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

VRTX’s price/forward earnings is 19.23.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

VRTX’s price/book is 6.33.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See VRTX’s valuation ratios compared to the Market Index.

VRTX’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare VRTX’s historical performance against its industry peers and the overall market.